StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Ultra-Rare Products by Quarter

Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — U.S. product sales ($M) ($M)

QuarterlyAnnual

Amgen Ultra-Rare Products: $144M in Q2 2026, down 17.7% from a year earlier.

Latest, Q2 2026
144
Period ended Jun 30, 2026
Change on a year earlier
-17.7%
175 in Q2 2025
History
11 quarters
Since Q4 2023
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

“|| Ultra-Rare products (1) | 144 | 5 | 149 | 183 | (19%)”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 8-K Product Sales Detail & Form 10-Q / 10-K Other Product Sales Footnote.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedUltra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — U.S. product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026144-17.7%Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202696-43.9%Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 2025144-29.8%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025195+8.3%Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 20251750.0%Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 2025171+3.0%Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 2024205+26.5%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024180–Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024175–Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 2024166–Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 2023162–Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗

Cite this data

StockData. (2026). Amgen Ultra-Rare Products ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-ultra-rare-us

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.